FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994073132> ?p ?o ?g. }

• W2994073132 endingPage "e112" @default.
• W2994073132 startingPage "e104" @default.
• W2994073132 abstract "Although experts have recommended testing for pretreatment drug resistance (PDR) before antiretroviral therapy (ART) initiation, there is little evidence to support its implementation. We aimed to establish whether an inexpensive point mutation assay can improve virological suppression by identifying PDR to guide drug selection for ART in a lower-middle income country.Investigators did an open-label, randomised controlled trial at three HIV treatment sites in Kenya: two in Nairobi and one in rural Maseno. Individuals (aged ≥2 years) were eligible to participate if they were confirmed HIV-seropositive, qualified for first-line ART, planned to reside in the area for more than 1 year, and provided informed consent. We randomly assigned participants (1:1) to either PDR testing by oligonucleotide ligation assay (OLA) to guide selection of ART or to standard of care, which did not include OLA testing. The OLA-guided therapy group had pre-ART peripheral blood mononuclear cells evaluated for drug resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) at codons Lys103Asn, Tyr181Cys, Gly190Ala, and to lamivudine at Met184Val, and when at least one drug-resistant codon was detected in a participant's pre-ART specimen, clinicians were directed to prescribe protease inhibitor-based second-line ART. Those without detected resistance and those who were randomised to standard of care received NNRTI-based first-line ART. The primary outcome was plasma HIV-1 RNA of at least 400 copies per mL at 4, 8, or 12 months after ART initiation, which defined virological failure, assessed in all participants who received treatment (data were censored for those lost-to-follow-up or who died). The study has been completed and is registered with ClinicalTrials.gov, NCT01898754.We screened 1198 participants between May 28, 2013, and Nov 4, 2014, of whom 991 (83%) were enrolled (492 received OLA and 495 received standard of care; four did not begin treatment). 93 participants (prevalence 9·4%) had PDR (95% CI 7·7-11·4). 34 (8·5%) of 400 participants in the OLA group had virological failure at month 12 of ART (95% CI 6·0-11·7) compared with 39 (9·7%) of 402 (7·0-13·0) in the standard-of-care group (log-rank p=0·26). Among participants with PDR, virological failure was lower in the OLA-guided therapy group than in the standard-of-care group: five (14%) of 35 compared with 13 (50%) of 26; p=0·0020). Among those prescribed NNRTI-based ART, participants given efavirenz were less likely to have virological failure than were those receiving nevirapine (odds ratio 0·37, 95% CI 0·22-0·62; p<0·0001). The OLA-guided therapy group had 39 serious non-lethal adverse events and 34 deaths. The standard-of-care group had 34 severe adverse events and 43 deaths, differences that were not significant. Adverse events judged to potentially be due to ART were few and similar between groups, with 17 (16%) in the OLA-guided therapy group and 16 (16%) in the standard-of-care group (p=0·90).Our finding that OLA testing for PDR reduced virological failure in only those with specific PDR mutations suggests that PDR poses less of a risk for virological failure than that predicted by past prevalence estimates, and that the value of PDR testing to reduce virological failure should be assessed for antiretroviral treatment regimens.US National Institutes of Health." @default.
• W2994073132 created "2019-12-13" @default.
• W2994073132 creator A5012456772 @default.
• W2994073132 creator A5013081084 @default.
• W2994073132 creator A5013314547 @default.
• W2994073132 creator A5019571738 @default.
• W2994073132 creator A5020991784 @default.
• W2994073132 creator A5025166250 @default.
• W2994073132 creator A5029038051 @default.
• W2994073132 creator A5045684920 @default.
• W2994073132 creator A5046862089 @default.
• W2994073132 creator A5058999949 @default.
• W2994073132 creator A5059164563 @default.
• W2994073132 creator A5059572608 @default.
• W2994073132 creator A5062140515 @default.
• W2994073132 creator A5062463517 @default.
• W2994073132 creator A5089881729 @default.
• W2994073132 date "2020-02-01" @default.
• W2994073132 modified "2023-10-18" @default.
• W2994073132 title "Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial" @default.
• W2994073132 cites W1607406129 @default.
• W2994073132 cites W2020355960 @default.
• W2994073132 cites W2038756830 @default.
• W2994073132 cites W2051469592 @default.
• W2994073132 cites W2086783015 @default.
• W2994073132 cites W2103414045 @default.
• W2994073132 cites W2117707156 @default.
• W2994073132 cites W2118784602 @default.
• W2994073132 cites W2119030872 @default.
• W2994073132 cites W2126014281 @default.
• W2994073132 cites W2129120084 @default.
• W2994073132 cites W2133758885 @default.
• W2994073132 cites W2134746895 @default.
• W2994073132 cites W2139311359 @default.
• W2994073132 cites W2141776019 @default.
• W2994073132 cites W2167426110 @default.
• W2994073132 cites W2467247336 @default.
• W2994073132 cites W2762751259 @default.
• W2994073132 cites W2773554166 @default.
• W2994073132 cites W2793697081 @default.
• W2994073132 cites W2794989305 @default.
• W2994073132 cites W2795103913 @default.
• W2994073132 cites W2806532709 @default.
• W2994073132 cites W2896615022 @default.
• W2994073132 cites W2909647196 @default.
• W2994073132 doi "https://doi.org/10.1016/s2352-3018(19)30337-6" @default.
• W2994073132 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6936934" @default.
• W2994073132 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31818716" @default.
• W2994073132 hasPublicationYear "2020" @default.
• W2994073132 type Work @default.
• W2994073132 sameAs 2994073132 @default.
• W2994073132 citedByCount "14" @default.
• W2994073132 countsByYear W29940731322020 @default.
• W2994073132 countsByYear W29940731322022 @default.
• W2994073132 countsByYear W29940731322023 @default.
• W2994073132 crossrefType "journal-article" @default.
• W2994073132 hasAuthorship W2994073132A5012456772 @default.
• W2994073132 hasAuthorship W2994073132A5013081084 @default.
• W2994073132 hasAuthorship W2994073132A5013314547 @default.
• W2994073132 hasAuthorship W2994073132A5019571738 @default.
• W2994073132 hasAuthorship W2994073132A5020991784 @default.
• W2994073132 hasAuthorship W2994073132A5025166250 @default.
• W2994073132 hasAuthorship W2994073132A5029038051 @default.
• W2994073132 hasAuthorship W2994073132A5045684920 @default.
• W2994073132 hasAuthorship W2994073132A5046862089 @default.
• W2994073132 hasAuthorship W2994073132A5058999949 @default.
• W2994073132 hasAuthorship W2994073132A5059164563 @default.
• W2994073132 hasAuthorship W2994073132A5059572608 @default.
• W2994073132 hasAuthorship W2994073132A5062140515 @default.
• W2994073132 hasAuthorship W2994073132A5062463517 @default.
• W2994073132 hasAuthorship W2994073132A5089881729 @default.
• W2994073132 hasBestOaLocation W29940731322 @default.
• W2994073132 hasConcept C114851261 @default.
• W2994073132 hasConcept C126322002 @default.
• W2994073132 hasConcept C142462285 @default.
• W2994073132 hasConcept C159047783 @default.
• W2994073132 hasConcept C168563851 @default.
• W2994073132 hasConcept C2522874641 @default.
• W2994073132 hasConcept C2777351918 @default.
• W2994073132 hasConcept C2777447569 @default.
• W2994073132 hasConcept C2777869810 @default.
• W2994073132 hasConcept C2780593183 @default.
• W2994073132 hasConcept C2781143361 @default.
• W2994073132 hasConcept C2781413609 @default.
• W2994073132 hasConcept C2993143319 @default.
• W2994073132 hasConcept C3013748606 @default.
• W2994073132 hasConcept C71924100 @default.
• W2994073132 hasConcept C86803240 @default.
• W2994073132 hasConcept C89423630 @default.
• W2994073132 hasConcept C98274493 @default.
• W2994073132 hasConceptScore W2994073132C114851261 @default.
• W2994073132 hasConceptScore W2994073132C126322002 @default.
• W2994073132 hasConceptScore W2994073132C142462285 @default.
• W2994073132 hasConceptScore W2994073132C159047783 @default.
• W2994073132 hasConceptScore W2994073132C168563851 @default.
• W2994073132 hasConceptScore W2994073132C2522874641 @default.
• W2994073132 hasConceptScore W2994073132C2777351918 @default.
• W2994073132 hasConceptScore W2994073132C2777447569 @default.

• next